Nxera Pharma: We have received a USD 35 million milestone from Neurocline due to the positive results of the Phase 2 clinical trial of the candidate NBI-1117568 for schizophrenia

JPX · Sep 2 07:30

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.